APLLTD:NSE-Alembic Pharmaceuticals Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 961.50

Change

+21.55 (+2.29)%

Market Cap

INR 189.14B

Volume

0.95M

Average Target Price

INR 1,154.00 (+20.02%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients (API) and formulations. The company also provides branded and generic formulations in various therapeutic areas, such as cardio-diabetic, gynecology, acute, gastroenterology, ophthalmology, dermatology, urology, orthopedics, cancer, inflammation, autoimmune diseases, anti-infective, cold and cough, and metabolic disorders, as well as hospital care and animal health. In addition, it exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India. Address: Alembic Road, Vadodara, India, 390003

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-25 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

+11.20 (+1.95%)

INR1,406.97B 95.33 35.28
DIVISLAB:NSE Divi's Laboratories Limited

+24.35 (+0.69%)

INR947.47B 53.86 39.67
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

+45.50 (+0.90%)

INR842.73B 54.99 25.69
AUROPHARMA:NSE Aurobindo Pharma Limited

+74.80 (+8.10%)

INR585.12B 18.62 10.42
LUPIN:NSE Lupin Limited

+2.65 (+0.25%)

INR490.79B 49.28 19.69
CADILAHC:NSE Cadila Healthcare Limited

+6.90 (+1.50%)

INR480.03B 28.35 17.29
ALKEM:NSE Alkem Laboratories Limited

+75.40 (+2.48%)

INR371.88B 25.39 17.31
IPCALAB:NSE Ipca Laboratories Limited

-63.10 (-3.09%)

INR251.52B 25.17 17.52
LAURUSLABS:NSE Laurus Labs Limited

+9.00 (+2.43%)

INR203.72B 34.01 20.19
NATCOPHARM:NSE NATCO Pharma Limited

-10.65 (-1.18%)

INR163.01B 31.16 19.83

ETFs Containing APLLTD

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.78% 29% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.78% 29% F 25% F
Trailing 12 Months  
Capital Gain 56.44% 47% F 79% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 56.44% 47% F 79% C+
Trailing 5 Years  
Capital Gain 60.24% 63% D 69% D+
Dividend Return 2.92% 59% F 32% F
Total Return 63.15% 63% D 68% D+
Average Annual (5 Year Horizon)  
Capital Gain 13.15% 63% D 73% C
Dividend Return 0.69% 71% C- 49% F
Total Return 13.83% 61% D- 73% C
Risk Return Profile  
Volatility (Standard Deviation) 34.56% 66% D 58% F
Risk Adjusted Return 40.02% 69% D+ 81% B-
Market Capitalization 189.14B 86% B 89% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 16.00 78% C+ 58% F
Price/Book Ratio 4.42 36% F 19% F
Price / Cash Flow Ratio 42.11 25% F 10% F
EV/EBITDA 13.34 58% F 45% F
Management Effectiveness  
Return on Equity 28.00% 95% A 95% A
Return on Invested Capital 18.48% 89% B+ 90% A-
Return on Assets 14.42% 94% A 97% A+
Debt to Equity Ratio 27.55% 22% F 38% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.69 66% D 76% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.